NEU is a buy recommendation on The Bull
18 Share Tips – 6 September 2021 - The Bull
https://thebull.com.au/18-share-tips-6-september-2021/
NEU is developing drug therapies to treat neurological disorders that emerge in early childhood. Top line results from its phase 3 trial of lead compound trofinetide – for Rett syndrome – are expected in the fourth quarter of 2021. If all goes to plan and trofinetide is approved and launched in the US, the company is forecasting potential revenue of $A111 million in the US alone, plus royalties on net sales, during 2022 and 2023. However, most pharmaceutical companies carry a degree of risk.
- Forums
- ASX - By Stock
- Ann: Trofinetide Rett syndrome clinical trial in girls aged 2-5
NEU is a buy recommendation on The Bull 18 Share Tips – 6...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.626B |
Open | High | Low | Value | Volume |
$20.00 | $20.66 | $19.94 | $6.415M | 314.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1024 | $20.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.53 | 285 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1475 | 22.020 |
1 | 98 | 21.740 |
10 | 5544 | 21.550 |
10 | 11465 | 21.540 |
4 | 1124 | 21.180 |
Price($) | Vol. | No. |
---|---|---|
18.470 | 2461 | 2 |
19.250 | 1 | 1 |
19.380 | 2183 | 1 |
19.490 | 2021 | 5 |
19.500 | 400 | 1 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
NEU (ASX) Chart |